Skip to main content
Premium Trial:

Request an Annual Quote

Ambit, Bristol Myers-Squibb Expand Kinase Screening Pact

NEW YORK (GenomeWeb News) - Ambit Biosciences has expanded an agreement with Bristol-Myers Squibb for kinase discovery research, Ambit said today.
Under the agreement, Ambit will use its KinomeScan method to screen small-molecule libraries against "a large number of human kinases," Ambit said, continuing a relationship begun in 2004.
Ambit's KinomeScan uses binding assays to determine how compounds bind to intended and unintended kinases, the company said.
The agreement calls for Bristol Myers-Squibb to give Ambit an undisclosed cash payment on the front end, and Ambit will retain the rights to certain of Bristol Myers-Squibb's preclinical and clinical compounds.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.